Active Ingredient History
Danazol is a synthetic derivative of ethisterone which is approved by FDA for the treatment of endometriosis, fibrocystic breast disease and for preventing hereditary angioedema. It is believed that the in vivo therapeutic effect is achieved through activating androgen receptors. Danazol has teratogenic effects. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Endometriosis (approved 1996)
Fibrocystic Breast Disease (approved 1996)
Hereditary Angioedema Types I and II (approved 1996)
Anemia (Phase 2)
Anemia, Aplastic (Phase 1/Phase 2)
Blood Coagulation Disorders (Phase 2)
Breast (Phase 2)
Cyclosteroids (Phase 2)
Dyskeratosis Congenita (Phase 2)
Endometrial Neoplasms (Phase 2)
Endometriosis (Phase 4)
Fanconi Anemia (Phase 1/Phase 2)
Fibrocystic Breast Disease (Phase 2)
Healthy Volunteers (Phase 1)
Infertility (Phase 4)
Inosine Triphosphate (Phase 2)
Liver Cirrhosis (Phase 2)
Lung Transplantation (Phase 1/Phase 2)
Macular Edema (Phase 3)
Myelodysplastic Syndromes (Phase 2/Phase 3)
Ovarian Cysts (Phase 4)
Physiological Effects of Drugs (Phase 2)
Polycythemia Vera (Phase 3)
Primary Myelofibrosis (Phase 3)
Pulmonary Fibrosis (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 2)
Purpura, Thrombotic Thrombocytopenic (Phase 2)
Telomere (Phase 2)
Telomere Shortening (Phase 2)
Thrombocytopenia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
